By Angela Gennari. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

People love us!

User reviews

"Love the offline function"
"This is "the" way to handle your podcast subscriptions. It's also a great way to discover new podcasts."

Episode 38: Dr. Leen Kawas

1:06:04
 
Share
 

Manage episode 350279128 series 3323657
By Angela Gennari. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Dr. Leen Kawas has shattered ALL the glass ceilings in her quest to chase the American Dream. As a researcher, inventor and founder of a bioscience company, Leen fueled her passion for change with innovation and tenacity, while raising $400 million to lead her company into a groundbreaking IPO.

Dr. Kawas is the Managing General Partner of Propel Bio Partners. She is the co-founder of Athira and a co-inventor of its lead drug candidate ATH-1017, and also invented several of the innovative drug candidates in Athira’s pipeline. ​ Dr. Kawas served as Athira’s chief executive officer and president, and as a member of its board of directors from January 2014-2021. In this role, she led the technological and financial growth of Athira, raising around $400M and taking the company through its public offering. According to Business Insider and GeekWire, Dr. Kawas was one of only 22 female founders and CEOs to lead their company to an IPO, as of February 2021, and was the first woman to guide a company through an IPO in Washington State in over 20 years (at the time of Athira’s IPO in September 2020).

Join us for this in-depth talk about Dr. Kawas' journey through the IPO process, the need for women at the executive level and why bioscience is so personal for her.

  continue reading

61 episodes

Share
 
Manage episode 350279128 series 3323657
By Angela Gennari. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Dr. Leen Kawas has shattered ALL the glass ceilings in her quest to chase the American Dream. As a researcher, inventor and founder of a bioscience company, Leen fueled her passion for change with innovation and tenacity, while raising $400 million to lead her company into a groundbreaking IPO.

Dr. Kawas is the Managing General Partner of Propel Bio Partners. She is the co-founder of Athira and a co-inventor of its lead drug candidate ATH-1017, and also invented several of the innovative drug candidates in Athira’s pipeline. ​ Dr. Kawas served as Athira’s chief executive officer and president, and as a member of its board of directors from January 2014-2021. In this role, she led the technological and financial growth of Athira, raising around $400M and taking the company through its public offering. According to Business Insider and GeekWire, Dr. Kawas was one of only 22 female founders and CEOs to lead their company to an IPO, as of February 2021, and was the first woman to guide a company through an IPO in Washington State in over 20 years (at the time of Athira’s IPO in September 2020).

Join us for this in-depth talk about Dr. Kawas' journey through the IPO process, the need for women at the executive level and why bioscience is so personal for her.

  continue reading

61 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Player FM - Podcast App
Go offline with the Player FM app!

Quick Reference Guide

Copyright 2023 | Sitemap | Privacy Policy | Terms of Service